Objectives:~Primary Objectives~1. Compare progression-free survival at 3 years with historical control rate of 50%.~Primary endpoint~1. Progression-free survival at 3 years, measured from the date of transplant to the date of progression or death.~Secondary objectives:~Assess minimal residual disease (MRD) rate at 12 months after starting Isatuximab maintenance therapy~Assess overall best response rate (defined as the occurrence of VGPR or better and CR/sCR) before the 4th Isatuximab cycle, and at 12, 24, and 36 months after starting maintenance therapy~Assess MRD rate before 4th Isatuximab cycle and at 24 months after starting maintenance therapy~Assess duration of response (DOR)~Assess overall survival (OS)~Assess safety
To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).